Status:
COMPLETED
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Lead Sponsor:
Pharmacyclics LLC.
Conditions:
Breast Neoplasms
Ovarian Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, t...
Eligibility Criteria
Inclusion
- At least 18 years old
- Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme
- ECOG performance status score either 0, 1, or 2
- Willing and able to provide written informed consent
Exclusion
- Greater than two prior cytotoxic regimens
- Laboratory values showing adequate function of bone marrow, liver, and kidneys
- Uncontrolled hypertension
- Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00120939
Last Update
April 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213